Navigation Links
Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2014
Date:7/25/2013

cilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables to FollowABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedJune 30,20132012Revenues

$
43,169

$
42,014Cost of revenues

22,277

19,165Gross profit

20,892

22,849Operating expenses:Research and development 

3,173

2,965Sales and marketing 

10,028

11,769General and administrative

3,055

3,322Total operating expenses

16,256

18,056Income from operations

4,636

4,793Interest and other income (expense), net

404

(230)Income before income tax provision

5,040

4,563Income tax provision

1,811


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abaxis, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
3. Abaxis To Report First Quarter Fiscal Year 2013 Financial Results Thursday, July 26, 2012
4. Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2013
5. Abaxis, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
7. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
8. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
9. Abaxis Announces the Launch of Kidney Profile Plus Panel
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 ... the "Pharmaceutical Contract Manufacturing - Global Strategic Business ... This report analyzes the worldwide markets for Pharmaceutical Contract ... Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms ... (Syrups, Suspensions, Gels, Creams & Ointments). The ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... 2014  Boehringer Ingelheim today announced that the ... review the New Drug Application (NDA) for the ... via the Respimat ® inhaler for the ... airflow obstruction in patients with chronic obstructive pulmonary ... + olodaterol FDC will not be indicated to ...
Breaking Medicine Technology:Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... Data from Serial Outpatient Infusion Study in Patients ... of Cardiology 56th Annual Scientific Session --, MOUNTAIN ... -- Scios Inc. announced today that an exploratory,920-patient, ... effect on the primary endpoint, a composite of ...
... March 26, 2007 /PRNewswire/ -- A large ... CYPHER(R) Sirolimus-eluting,Coronary Stent reported favorable safety and ... investigators at the of,Cardiology's 56th Annual Scientific ... a prospective, single-arm study designed,to evaluate the ...
Cached Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 2Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 3Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 4
(Date:8/20/2014)... In a recent article published by the ... (UCL) study showed that dental experts from around the ... was the most effective. Analysis of 66 different advice ... frequently recommended, but none were favored by a majority. ... experienced cosmetic dentist Dr. Patrick J. Broome, DMD, ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 ... consecutive year on its 33rd annual Inc. 500|5000, ... companies. The list represents the most comprehensive look ... independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, ... well-known names gained early exposure as members of ...
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sodium Chloride IV . ... lot of Sodium Chloride IV 0.9%, USP 1000 mL, by ... presence of particulate matter. Sodium Chloride Injection, USP is used ... priming solution in hemodialysis procedures. , The reason ...
(Date:8/20/2014)... Kowa Optimed returns after a short hiatus ... new SL-17 portable slit lamp. , The SL-17 has ... controlled by an illuminated thumb wheel for easy adjustments ... available AAA rechargeable and dry cell batteries, which is ... designed specifically for the device. The new Sl-17 base ...
Breaking Medicine News(10 mins):Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2
... the greater the chances , TUESDAY, May 4 (HealthDay ... her baby,s risk of developing psychiatric problems in childhood ... While there,s plenty of evidence that smoking during pregnancy ... such as asthma, ear infections and respiratory disease, this ...
... In an ... Program will be moving into a bigger office location on April 26. , ... Cincinnati, OH (PRWEB) May 4, 2010 -- The continued success ... facility away from their existing location on Pine Road in Kenwood. The office now occupies a ...
... ... LLP have again been named as Ohio Super Lawyers®. This honor, by the much respected ... accomplished medical malpractice attorneys. Congratulations! , ... Cleveland, OH (PRWEB) May 4, 2010 -- Spangenberg lawyers were again honored this ...
... ... prognostic testing system for individual patients announces new publications in major disease conditions validating ... US catch-up? , ... Michigan (Vocus) May 4, 2010 -- PrognostiCheck®, the noninvasive assessment of the presence, severity ...
... for providing better care to patients could end up ... belonging to racial and ethnic minorities, according to a ... a typical pay-for-performance program medical practices that serve vulnerable ... a result of existing gaps in the quality of ...
... experts add that painkiller,s other health benefits may outweigh possible ... British study finds that people who take aspirin every day ... devastating digestive illness. , But it,s still not very likely ... lead author said patients should keep in mind that aspirin ...
Cached Medicine News:Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 2Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 3Health News:UniqueU Medical Weight Loss Success Requires an Expansion and Move to a Larger Location 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers on 2010 List 3Health News:"IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do 2Health News:"IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do 3Health News:Pay-for-performance programs may worsen medical disparities, study finds 2Health News:Pay-for-performance programs may worsen medical disparities, study finds 3Health News:Aspirin May Increase Risk of Crohn's Disease 2
... Laser System is a solid state Holmium: ... in all areas of the urinary tract, ... , ,A variety of reusable fibers provide ... clinical versatility and outcomes. Standard 115V electrical ...
... offers increased bone surface area contact between ... management of nonunions in long bones., ,Grid-Like ... of Contact on Host Bone , ,The ... cathode offers increased surface area and a ...
... proud to offer one of ... market at only 188 grams! ... a superior flow rate with ... mechanisms. The complementing electrodes provide ...
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
Medicine Products: